ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Abstract Number: OC 58.4

    Ibrutinib inhibits BMX-dependent endothelial VCAM-1 expression in vitro and pro-atherosclerotic endothelial activation and platelet adhesion in vivo

    T. Kohs1, S. Olson1, K. Jordan1, T. Zheng1, A. Xie1, J. Hodovan1, M. Muller1, C. McArthur1, J. Johnson1, B. Sousa2, M. Wallisch3, P. Kievit4, J. Aslan1, J. Seixas2, G. Bernardes5, M. Hinds1, J. Lindner1, O. McCarty6, C. Puy1, J. Shatzel1

  • Abstract Number: PB0525

    Icodextrin as anti- adherence molecule affects cancer cells attachment to the fibrin deposits on the peritoneum surface

    I. aldybiat1, S. Mirshahi2, J. Soria1, M. Pocard1, M. Mirshahi3

  • Abstract Number: OC 65.4

    Idarucizumab for Reversal of Dabigatran: Multicenter Real-World Experience

    P. Barzallo Burbano1, C. Fernández Maqueda2, M. Meijón3, N. Revilla3, M. Blanco Bañares4, B. Fernández5, R. Rodríguez González6, M. Sola Aparicio7, B. Rosado Sierra7, S. Asenjo8, I. Gutiérrez Jomarrón9, P. Pilar Llamas Sillero10, P. Prieto Martínez2, R. De Santiago Álvarez2, J. Díez Martín11, G. Pérez Rus1, C. Pascual Izquierdo11

  • Abstract Number: VPB1165

    IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy

    G. Castaman1, A. Tagliaferri2, A. Molinari3, F. Peyvandi4, A. Coppola5, A. Finardi6, I. Schiavetti7, D. Vaccari8, A. Rocino9

  • Abstract Number: PB0337

    Identification and characterisation of ANKRD26-related thrombocytopenia in patients from the GAPP cohort.

    H. Vyas1, G. Lowe2, N. Morgan1

  • Abstract Number: VPB1251

    Identification and evaluation of novel variants associated with platelet function disorders by NGS-based high-throughput sequencing

    H. Schulze1, A. Borst2, E. Klopocki2, O. Andres3

  • Abstract Number: PB1029

    Identification and functional characterisation of alternatively spliced novel isoforms of human protein C (PROC) gene

    S. Abul Kalam1, F. Naaz2

  • Abstract Number: PB1276

    Identification of a red cell hemostatic mechanism causing COVID-19 microvascular obstruction

    Y. Yuan1, M. Wu2, I. Alwis3, R. Smythe3, J. Maclean3, t. Woodruff4, T. Barrett5, a. rapkiewicz6, J. Shaun7

  • Abstract Number: OC 74.4

    Identification of a site on Factor XII required for interactions with polyphosphate and other soluble polyanions

    A. Shamanaev1, M. Litvak2, S. Dickeson2, D. Gailani3

  • Abstract Number: OC 68.1

    Identification of non-coding genomic regions involved in the aetiology of bleeding, platelet, and thrombotic disorders.

    L. Stefanucci1, M. Sims2, J. Lambourne3, F. Burden4, L. Grassi4, D. Seyres5, J. Stephens5, R. Tomaz5, F. Lugtu5, D. Greene5, N. Owens6, K. Megy5, S. Sivapalaratnam7, K. Freson8, L. Vallier5, E. Turro9, W. Ouwehand10, M. Frontini6

  • Abstract Number: PB0390

    Identification of novel inhibitors of the platelet collagen receptor GPVI by a phenotypic screening assay

    S. Troitiño1, I. Izquierdo2, N. Gómez-Romero2, F. Rodríguez Del Río2, G. Prieto Da Cuña2, L. Hermida-Nogueira1, E. Domínguez3, M. Loza4, Á. García1

  • Abstract Number: OC 34.5

    Identification of risk factors for major bleeding during anticoagulation and recurrent venous thromboembolism after its discontinuation in patients with a first unprovoked venous thromboembolism.

    C. Gabara1, Y. Yamashita2, J. Aibar1, C. Zamora3, J. Moisés1, C. FONT1, R. Valle4, A. Bura-Riviere5, L. Mazzolai6, A. Lorenzo7, A. Ballaz8, O. Madridano9, J. Suriñach10, J. Fernández-Reyes11, A. Villalobos12, P. Verhamme13, J. López-Sáez14, A. Gil-Díaz15, J. Vela16, M. Monreal17

  • Abstract Number: VPB0437

    Identifying Clinical Predictors for Thrombus Progression in Cirrhotic Patients with Untreated Splanchnic Vein Thrombosis

    H. McMurry1, J. Sabile1, B. Elstrott1, B. Chobrutskiy1, A. Mohinani2, S. Patel1, S. Gowda1, J. Shatzel2

  • Abstract Number: OC 32.1

    Identifying novel stabilin-2 plasma ligands using proximity labeling

    M. Underwood, K. Golden, K. Desch

  • Abstract Number: OC 23.5

    Identifying phenotypes of deep vein thrombosis and their relation to clinical outcomes beyond recurrence

    A. Iding1, A. Pallares Robles2, V. ten Cate3, H. ten Cate4, P. Wild3, A. ten Cate-Hoek5

  • Abstract Number: OC 31.5

    Identifying which emergency department patients should be tested for pulmonary embolism

    D. Christopher1, K. Grewal2, S. Ghazalbash3, F. Mowbray3, M. Zargoush3, K. de Wit4

  • Abstract Number: OC 43.1

    Idntification of a von Willebrand factor homozygous deep intronic variant by next-generation analysis, and subsequent validation by mRNA analysis and study of the patient-derived endothelial cells

    H. Yadegari1, M. Jamil2, J. Oldenburg3

  • Abstract Number: VPB0610

    IL-2 (T330G) gene promoter polymorphism and its effect on lymphocyte-platelet adhesion in patients with coronavirus infection SARS-COV-2 (COVID-19)

    A. Emelyanov, A. Emelyanova, E. Zaytseva, Y. Vitkovsky

  • Abstract Number: OC 20.4

    IL-6 is a Biomarker for Joint Bleeds in Hemophilia

    L. Knowles1, C. Wolter2, L. Beyer1, M. Menger3, M. Laschke3, U. Grün4, E. Hermann5, J. Pilch6

  • Abstract Number: OC 04.5

    Immune Medicated Thrombotic Thrombocytopenic Purpura relapse is associated with HLA-DRB1*15:01

    M. Stubbs1, A. Doyle2, C. Cheshire3, A. Levine3, M. Thomas4, J. Westwood1, R. Kleta3, D. Gale3, H. Stanescu3, M. Scully1

  • Abstract Number: PB1053

    Immunophenotyping and cell sorting of human MKs from human primary sources or differentiated in vitro from hematopoietic progenitors

    A. Acebes-Huerta1, P. Martínez-Botía1, C. Martín Martín1, A. Bernardo2, A. R. Rodríguez3, M. Vicente-Ayuso4, C. Benavente Cuesta5, L. Gutiérrez6

  • Abstract Number: PB0309

    Immunoprofiles and open ADAMTS13 in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

    K. Sakai1, M. Matsumoto2, L. De Waele3, C. Dekimpe3, C. Tersteeg4, S. De Meyer4, E. Hamada5, M. Kubo2, K. Vanhoorelbeke4

  • Abstract Number: PB0660

    Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: an ex-vivo study.

    L. Bounaix1, O. Bulla2, P. Fontana2

  • Abstract Number: PB0789

    Impact of age on in vitro metabolism of clopidogrel: a potential explanation for high on-treatment platelet reactivity in elderly?

    A. PONTIS1, X. DELAVENNE2, M. VERDIER3, S. HODIN4, A. ANDRIAMAHARO5, P. GUERET6, F. NEDELEC-GAC6, P. GAUSSEM7, C. BACHELOT-LOZA8, I. Gouin1

  • Abstract Number: VPB0939

    Impact of Age-adjusted International Prognostic Index for Predicting Venous Thromboembolism in Thai Patients with Diffuse Large B-cell Lymphoma

    N. Hantrakun1, P. Phinyo2, A. Tantiworawit1, E. Rattaritamrong1, C. Chai-Adisaksopha1, T. Rattanathammethee1, S. Hantrakool1, P. Piriyakhuntorn1, T. Punnachet1, P. Niprapan1, L. Norasetthada1

  • Abstract Number: PB0987

    Impact of amotosalen/UVA process for pathogen reduction in platelet concentrates on transfusion efficiency in cardiac surgery

    B. Belkacem1, H. Hamzeh-Cognasse2, A. Duchez3, M. Eyraud4, C. Arthaud4, A. Prier5, E. Audoux6, T. Ebermeyer7, P. Chavarin4, A. Kazra1, J. Morel8, J. Palao8, F. Cognasse6

  • Abstract Number: PB0381

    Impact of Coagulation Factor XI (FXI) on the Binding of Platelet Glycoprotein Ibα to the von Willebrand Factor A1 Domain

    M. Nakayama1, S. Goto2, S. Takemoto3, H. Oka2, H. Yokota3, S. Takagi4

  • Abstract Number: PB0092

    Impact of COVID-19 pandemic on pulmonary embolism incidence and characteristics: a 24 months perspective

    p. sterpone1, M. MERONI2, W. Ageno3, M. Donadini4

  • Abstract Number: PB1338

    Impact of COVID-19 pandemic on VTE investigation and diagnosis rate in Belfast Health and Social Care Trust, Northern Ireland.

    N. Sotiropoulou1, S. Hannan2, G. Benson3, R. Gooding4, C. Neill3, C. Corrigan4

  • Abstract Number: PB1154

    Impact of emicizumab on anticoagulant drugs at therapeutic concentrations using thrombin generation assay

    B. Leroy1, B. Gillet1, M. Brionne Francois1, Y. REPESSE2

  • Abstract Number: PB0544

    Impact of fasting on INR in Ramadan on Muslim population taking warfarin.

    A. Jahangir, S. khan, M. Quraishi, A. Taqi

  • Abstract Number: PB1010

    Impact of fresh frozen plasma dosing in patients with a left ventricular assist device undergoing heart transplant

    P. Dobesh1, H. Brink2, M. Thorson1, T. Ruter1, M. Edwards1

  • Abstract Number: VPB1374

    Impact of implementation of primary thromboprophylaxis protocol in hospitalized hematologic malignancies patients.

    A. López Sacerio1, M. Tejeda Ramón1, M. Suárez Rodríguez1, J. Cruz Rodríguez1, A. Morales Helguera2

  • Abstract Number: PB1172

    Impact of inhibitors on the procoagulant efficacy of bypass agents or hemostatic factors in combination with emicizumab

    E. Arias Salgado1, A. Dos Santos1, E. Monzón Manzano1, P. Acuña1, M. Alvarez-Román2, M. Martín Salces1, M. Rivas Pollmar3, S. García Barcenilla4, N. Butta1, V. Jiménez Yuste5

  • Abstract Number: PB1288

    Impact of periodontal inflammation on the cardiac tissues in a murine model

    H. El Itawi1, F. Batool2, C. Stutz2, F. Zobairi-El Ghazouani3, O. Huck2, F. Toti2

  • Abstract Number: PB0764

    Impact of Puumala Hantavirus infection on primary haemostasis: potential mechanisms of thrombocytopenia

    A. Schmuckenschlager1, A. Assinger2, J. Wigren Byström3, A. Fors Connoly3, C. Ahlm3, M. Forsell3, W. Schrottmaier2

  • Abstract Number: PB0341

    Impact of SARS-CoV-2 Vaccination in Thrombotic Thrombocytopenic Purpura Patients

    M. Capecchi1, P. De Leo2, M. Biganzoli2, I. Mancini3, P. Agosti4, B. Ferrari5, R. Gualtierotti6, A. Artoni7, F. Peyvandi8

  • Abstract Number: PB0081

    Impact of the COVID-19 pandemic on anticoagulation control for patients using warfarin

    L. O'Loughlin1, S. Shah2, C. Hubbard2, G. Barnes3, M. Fang2, D. Kazi4, R. Patell4

  • Abstract Number: PB1062

    Impact of the variability between normal pooled plasma batches on normalized ratio and mixing time reference cut-off values in lupus anticoagulant testing

    J. Cabo1, R. Soleimani1, L. Morimont2, J. Baudar3, M. Guldenpfennig4, J. Douxfils2, F. Mullier5

  • Abstract Number: OC 60.2

    Impact of thrombophilia testing on treatment decision and outcome of thromboembolism and pregnancy morbidity: a single center retrospective cohort study

    K. Vrotniakaite-Bajerciene1, T. Tritschler2, K. Jalowiec3, H. Broughton3, J. Brodard3, A. Haynes4, A. Rovo3, J. Kremer Hovinga5, D. Aujesky6, A. Angelillo-Scherrer3

  • Abstract Number: PB1404

    Impact of Tissue factor promoter gene polymorphism with Recurrent pregnancy loss in India.

    K. Kishor1, A. Sharma1, S. Maharana2, C. Laha Roy2, R. Ranjan1, R. Kumar1, M. Mahapatra3, R. Saxena4

  • Abstract Number: PB0429

    Impact of venous thromboembolism on physical functioning: Results from a prospective cohort study

    D. Steiner1, S. Nopp2, B. Weber3, O. Schlager4, K. Janata-Schwatczek5, O. Königsbrügge1, F. Klok6, I. Pabinger7, C. Ay7

  • Abstract Number: VPB0577

    Impacts of antithrombotic agents on cellular physiology in the pancreatic tumoral environment

    H. Tran1, P. Van Dreden2, E. Mbemba3, I. Elalamy4, G. Gerotziafas5

  • Abstract Number: PB0217

    Impacts of Mim8 on routine coagulation assays, on intrinsic pathway coagulation factor assays and on thrombophilia coagulation tests

    L. Fauconnier1, N. Roland1, A. Carlo2, T. Hervé3, F. Depasse2, M. Ezban4, L. Nicoud1, N. Martineau1

  • Abstract Number: PB0085

    Impaired exercise capacity in Post-COVID syndrome: The role of VWF-ADAMTS13 axis

    N. Prasannan1, M. Heightman2, T. Hillman2, E. Wall2, R. Bell2, A. Kessler2, L. Neave3, A. Doyle4, A. Devaraj2, D. Singh5, H. Dehbi6, M. Scully1

  • Abstract Number: PB0765

    Impaired platelet function caused by Vibrio cholera outer membrane vesicles

    W. Schrottmaier1, A. Pirabe2, U. Resch2, J. Santol2, S. Frühwirth1, K. Aung3, M. Dongre3, A. Digruber4, B. Jilma5, A. Kirschner1, M. Ehling-Schulz4, S. Wai3, M. Forsell6, A. Assinger1

  • Abstract Number: VPB0568

    Implementation and scale-uping of Text Messages for primary care patients using Warfarin: a real life study

    V. CHAGAS1, M. Rego Souza-Silva2, M. Paiva Domingues3, D. Pereira2, L. Sá4, M. Almeida2, M. Raposo5, J. Oliveira6, T. Soares2, A. Baldoni7, M. Marcolino8, M. Parreiras Martins2

  • Abstract Number: PB1260

    Importance of Erythrocyte Arginase-1 for Vascular Smooth Muscle Cell NO Signaling and Calcification

    R. Gogiraju1, L. Renner2, M. Bochenek3, K. Zifkos4, M. Molitor2, P. Wenzel4, S. Danckwardt3, T. Münzel5, K. Schäfer4

  • Abstract Number: OC 50.3

    Improved Procoagulant Activity of Hemophilia B Causing Dysfunctional Factor IX Variants with Factor VIII Mimetics

    J. Chau1, A. Sternberg1, A. Pishko2, L. George1, B. Samelson-Jones1

  • Abstract Number: OC 11.3

    Improved Survival in Severely Bleeding Trauma Patients Treated with Low-titer Group O Whole Blood Compared to Component Therapy

    E. Mihalko*1, S. Shea2, K. Thomas3, M. Huff4, D. Scheurer5, G. Bochicchio6, P. Spinella7

  • Abstract Number: PB0658

    Improvement in school absence after factor replacement in students with haemophilia in Upper Assam, India

    A. Dutta, T. Dutta, D. Boruah

  • Abstract Number: PB1150

    Improvement in the Musculoskeletal Health and Quality of Life-Outcomes among Patients with Severe Hemophilia A with Inhibitor after 2 years of Personalised Physiotherapy

    M. Podolak-Dawidziak1, J. Zawilski2, M. Bober2, E. Stefańska-Windyga3, A. Buczma3, M. Biernat4

  • Abstract Number: OC 01.2

    Improvements in Health-Related Quality of Life in Adults with Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

    R. Itzler1, J. Miller2, R. Robson2, P. Monahan3, S. Pipe4

  • Abstract Number: PB0240

    Improving Discussion of Menstrual Cycle and Bleeding During Well-Child Visits at a Pediatric Residency Clinic

    A. Jackson1, A. Yamasaki2, E. Parker3, A. Close2

  • Abstract Number: PB0231

    Improving the provision of patient information regarding venous thromboembolism prevention at King’s College Hospital NHS Foundation Trust, London

    G. Giron1, E. Gee1, L. Georgiou2

  • Abstract Number: VPB0288

    Improving Thromboprophylaxis in Children Admitted to a Quaternary Care Children’s Hospital with COVID-19

    A. Yan1, C. Parsons2, G. Caplan3, D. Kelly4, J. Duzan5, E. Drake5, R. Kumar6

  • Abstract Number: PB0196

    In silico structural analysis of FVIII molecular changes from missense pathogenic variants in non-severe hemophilia A patients displaying FVIII:C discrepancy between one-stage vs chromogenic assays

    L. Rossetti1, B. Ziegler2, M. Arias3, R. Sueldo4, V. Marchione5, P. Radic6, M. Abelleyro7, A. Baqués8, C. De Brasi9

  • Abstract Number: PB0296

    In vitro characterization of a novel Arg102 mutation in the metalloprotease domain of ADAMTS13

    L. De Waele1, L. Vermeersch1, C. Tersteeg2, S. De Meyer2, K. Pavenski3, K. Vanhoorelbeke2

  • Abstract Number: VPB0571

    In vitro effects of colloidal silica on clotting of plasma with or without coagulation factor deficiencies, heparization, lupus anticoagulant positivity, or high fibrinogen concentration.

    A. Kadowaki1, M. Wakui2, Y. Fujimori3, H. Katagiri4, M. Murata2

  • Abstract Number: PB0829

    In Vitro Field Study Assessing How Clinical Hemostasis Laboratories Analyze Recombinant and Plasma-Derived von Willebrand Factor Products

    P. Turecek1, R. Ilk2, H. Gritsch1

  • Abstract Number: PB0816

    In vitro investigation of emicizumab efficacy and mode of action in vWD type 2 and 3 samples

    M. Locke1, N. Receveur1, A. Kiialainen2, T. David2

  • Abstract Number: PB0163

    In vitro monitoring of anti-coagulation therapy in whole blood using magnetic nanoparticles and susceptometry

    A. Harper1, A. Santana-Otero2, N. Telling1, D. Ortega3, D. Cabrera1

  • Abstract Number: PB0717

    In vitro Rescue of a Nonsense Mutation Responsible for Severe Coagulation Factor V Deficiency Using Ribosome Readthrough Agents

    A. Todaro1, M. Ciccone2, M. Serino2, D. Gemmati2, A. Cuneo2, T. Hackeng1, F. Bernardi3, E. Castoldi4

  • Abstract Number: PB0581

    In vivo activation of the contact pathway by thrombin in sterile models of DIC in baboons

    R. Keashari1, R. Silasi1, G. Regmi1, C. Lupu1, D. Gailani2, O. McCarty3, F. Lupu1

  • Abstract Number: OC 02.5

    In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)

    C. Field1, H. Kim2, M. Kowalska2, M. Weitzman2, G. Arepally3, D. Cines4, L. Rauova2, M. Poncz2

  • Abstract Number: PB0358

    In-depth analysis of the effects of unsteady flows on platelet release from suspensions of proplatelet-bearing megakaryocytes

    O. Boiron1, F. Lanza2, C. Strassel2, Y. KNAPP3

  • Abstract Number: PB1105

    In-vivo mimicking platelet thrombus formation in a microfluidic system (Anysis): Assessment of P2Y12 inhibitors for cardiology patients

    S. Shin1, S. Kim2, C. Choi3, J. Piao1

  • Abstract Number: VPB0108

    Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais

    K. Boonyawat, T. Phojanasenee, P. Noikongdee, P. Police, P. Chantrathammachart, P. Niparuck, T. Puavilai, A. Phuphuakrat, P. Angchaisuksiri

  • Abstract Number: PB1326

    Incidence of Pregnancy-associated Venous Thromboembolism: Second Nationwide Study

    H. Hwang1, S. Bang2, J. Lee3

  • Abstract Number: VPB0112

    Incidence of thrombotic events in a population affected by Covid-19 in a general hospital in Veracruz, Mexico

    L. Del Carpio-Orantes1, S. García-Méndez2, J. Sánchez-Díaz3, A. Rosas-Lozano3

  • Abstract Number: VPB0286

    Incidence, Risk Factors, and Outcome of Thrombotic Events in Pediatric Cancer Patients

    R. Çeçen1, D. Kızmazoğlu1, Ö. Tüfekçi2, Ş. Yılmaz2, D. İnce1, N. Olgun1, H. Ören3

  • Abstract Number: PB0906

    Incidences and Predictors of Venous Thromboembolism and Mortality in Patients Diagnosed with Lung Cancer among Saudi Population: Retrospective Two-Centre Cohort Study.

    R. Almesfir1, N. Alqudaibi2, F. Aleidan3

  • Abstract Number: PB0044

    Increased blood viscosity and red blood cell aggregation in patients with COVID-19

    C. Nougier1, E. Nader2, C. Boisson3, S. Poutrel4, J. CATELLA5, F. Martin2, J. Charvet2, S. Girard6, S. Havard-Guibert2, M. Martin2, H. Rezigue7, H. Desmurs-Clavel8, C. Renoux9, P. Joly9, N. Guillot2, Y. Bertrand10, A. Hot11, Y. Dargaud12, P. Connes4

  • Abstract Number: VPB0617

    Increased CD62P Platelet Expression in Deceased COVID-19 Patients

    U. Sukorini1, A. Arjana2, T. Triyono3, I. Trisnawati , A. Yun Jufan, N. Rahmi Ananda

  • Abstract Number: OC 66.4

    Increased Endothelial Secretion and Reduced Circulatory Clearance Contribute to Elevated Plasma von Willebrand Factor Levels in Multiple Myeloma

    C. Comerford1, S. Pal Singh Dhami2, P. Murphy3, S. Patmore2, S. Ward2, U. Budde4, J. O'Donnell2, S. Glavey3, J. Quinn3, J. O'Sullivan5

  • Abstract Number: VPB0420

    Increased expression of protein disulfide isomerase A1 on platelet surface in lupus anticoagulant-associated thrombosis

    A. Romer1, N. Samadi2, L. Hell1, C. Ay3, J. Gebhart4, I. Pabinger3

  • Abstract Number: PB0593

    Increased Percentage of Extended Aα Chain Fibrinogen (αE) in COVID-19 Patients

    J. de Vries1, C. Visser1, M. van Ommen2, C. Rokx3, E. van Nood3, E. van Gorp4, M. Goeijenbier5, J. van den Akker6, H. Endeman6, D. Rijken7, M. Kruip7, M. Weggeman2, J. Koopman2, M. de Maat8

  • Abstract Number: PB0857

    Increased Platelet Activation and Platelet-Leukocyte Aggregate Formation in Primary Sclerosing Cholangitis

    J. Gerwers1, H. Englert1, N. Wolska2, F. Glaser2, J. Hartl2, I. Schregel2, M. Sebode2, S. Steinmann2, J. Weltzsch2, C. Weiler-Normann2, C. Schramm3, T. Renné4, C. Deppermann5

  • Abstract Number: PB1228

    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.

    E. Campello1, A. Zanetto2, C. Bulato2, S. Gavasso2, F. Farinati2, F. Russo2, D. Tormene3, P. Burra2, M. Senzolo4, P. Simioni5

  • Abstract Number: PB0383

    Increased platelet procoagulant activity driven by fibrin-GPVI interaction alters clot structure

    J. Sandrin Gauer1, C. Duval2, R. Xu3, F. Macrae2, C. Tiede2, D. Tomlinson2, S. Watson4, R. Ariëns5

  • Abstract Number: OC 16.3

    Increased Rate and Risk Factors of Venous Thromboembolism (VTE) in Older Patients (pts) with Melanoma Receiving Chemotherapy and/or Immune Checkpoint Inhibitors (ICI): a SEER-Medicare Analysis

    T. Sussman1, L. Vu2, S. Markt2, S. Koroukian2, A. Khorana3

  • Abstract Number: PB0035

    Increased thrombus formation via procoagulant platelets in vaccine induced thrombotic thrombocytopenia (VITT)

    K. Althaus1, A. Singh2, L. Pelzl1, J. Zlamal3, I. Marini4, T. Backchoul3

  • Abstract Number: OC 27.3

    Individualized target trough FVIII level and optimized prophylaxis in pediatric patients with hemophilia A

    K. Huang1, D. Ai2, Y. Zhen2, G. Li2, Z. Chen2, R. Wu3

  • Abstract Number: OC 19.4

    Induction of myeloid cell hypercoagulability is a maladaptive consequence of trained immunity

    A. Rehill1, S. McCluskey2, G. Leon2, A. Curtis3, C. McMahon4, H. Charles-Messance5, F. Sheedy6, R. Preston2

  • Abstract Number: PB0456

    Inferior vena cava filter in a tertiary Hospital of Barcelona: a descriptive study of 185 cases.

    M. Montoya1, C. Gabara2, N. López2, A. Morancho2, J. Moisés2, C. FONT2, S. Jiménez2, F. Zarco2, M. Burrel2, P. Bermúdez2, E. Serrano2, J. Aibar2

  • Abstract Number: PB0590

    Inflammatory convalescent plasma to treat COVID-19: impact of amotosalen/UVA Pathogen Reduction Technology

    F. Cognasse1, H. Hamzeh-Cognasse2, A. Duchez3, M. Eyraud4, C. Arthaud4, A. Prier5, E. Audoux1, O. Hequet4, B. Bonneaudeau6, S. Rochette-Eribon4, F. Teyssier4, V. Barlet-Excoffier4, P. Chavarin4, D. Legrand4, P. Richard6, P. Morel6, P. Tiberghien6

  • Abstract Number: PB0589

    Inflammatory markers and auto-Abs to type I IFNs in COVID-19 Convalescent Plasma

    F. Cognasse1, H. Hamzeh-Cognasse2, B. Bonneaudeau3, C. Pierre3, J. Huet3, C. Arthaud4, M. Eyraud4, A. Prier5, O. Hequet4, A. Fillet3, P. Chavarin4, D. Legrand4, P. Richard3, F. Pirenne3, J. Casanova6, S. Susen7, P. Morel3, K. Lacombe8, P. Bastard6, P. Tiberghien3

  • Abstract Number: PB1269

    Inflammatory stimuli reveal a differential glycocalyx response between venous and arterial endothelial cells

    A. Milusev1, R. Rieben2, N. Sorvillo2

  • Abstract Number: PB0625

    Influence of centrifugation and residual platelet count on PAI-1 plasma level, euglobulin clot lysis time and global fibrinolytic capacity of plasma

    M. Bareille1, T. LECOMPTE2, F. Mullier3

  • Abstract Number: PB0059

    Influence of complement system genomic variations on the course of COVID-19

    J. Gumulec1, J. Máca2, J. Sagan3, J. Škarda4, M. Kutěj5, N. Chobolova6, D. Kaspřák7

  • Abstract Number: PB1074

    Influence of hemolysis, icterus and lipemia on Owren PT measured with a viscosity based detection coagulometer

    M. Held1, A. Hillarp2, A. Ståhlberg1

  • Abstract Number: VPB1278

    Influence of titanium dioxide particles on redox processes in human erythrocytes in vitro

    A. Skarabahatava1, M. Sadaunichuk1, E. Venskaya1, N. Aliakhnovich2

  • Abstract Number: PB1240

    Inherited Platelet Disorders Associated With Platelet Membrane Glycoproteins Abnormalities: A Portuguese Centre Experience

    P. Martinho1, C. Pinto2, J. Cabral3, J. Azevedo2, A. Roque2, O. Lavrukhina4, C. Catarino5, F. Rodrigues6, E. Antunes7, S. Batalha8, S. Nobre Fernandes9, M. Lopes10, C. Geraldes11, T. Fidalgo12

  • Abstract Number: PB1412

    Inherited thrombophilia and non-O blood type associated with recurrent spontaneous abortion.

    L. Spiezia1, A. Poretto2, E. Borella3, G. Turatti3, M. Marobin3, C. Simion3, E. Campello4, D. Tormene5, P. Simioni6

  • Abstract Number: PB0879

    Inhibition of apoptosis during cold storage of platelet concentrates better maintains both platelet functionality and survival

    I. Marini1, Y. Tamamushi1, C. Maettler1, L. Pelzl2, K. Althaus2, S. Nowak-Harnau3, T. Backchoul4

  • Abstract Number: PB0346

    Inhibition of PI3KC2alpha selectively reduces platelet recruitment after vascular injury while preserving thrombus architecture

    P. Larsson1, N. Setiabakti1, V. Tarlac2, A. McGovern3, J. Nunez-Iglesias4, K. Tunströmer5, J. Hamilton2, N. Boknäs6

  • Abstract Number: VPB0023

    Inhibition of restenosis after orbital atherectomy of severely calcified artery using combined electrohydraulic low level shock wave therapy and 125I- mediated gamma-intravascular brachytherapy

    H. Mehrad

  • Abstract Number: OC 77.1

    Inhibition of the Class II PI 3-kinase, PI3KC2a, prevents thrombosis in hyperlipidaemic mice

    N. Setiabakti1, V. Tarlac2, J. Hamilton2

  • Abstract Number: PB0376

    Inhibition of the p75 pan neurotrophic receptor partly mitigates BDNF-induced platelet aggregation

    S. Fleury1, I. Boukhatem2, M. Welman1, É. Maurand3, B. Allen1, H. Saragovi4, M. Lordkipanidzé1

  • Abstract Number: OC 22.2

    Inhibition of von Willebrand factor through stabilization of the ristocetin-binding site

    N. Arce, R. Li

  • Abstract Number: PB0668

    Inhibitor development is associated with decreased quality of life in patients with hemophilia

    M. Karimi1, S. Haghpanah2, M. Naderi3, S. Kamalian Fard2, H. Tavoosi4, S. Parand2, N. Javanmardi2

  • Abstract Number: PB0807

    Inhibitors in 3 patients with type 3 von Willebrand disease in a Portuguese Centre – management of bleeding and surgeries

    C. Catarino1, F. Rodrigues2, A. Pereira2, C. Peixoto3, L. Parusnikova3, J. Pestana4, S. Campaniço3, J. Lucas5, P. Afonso3

  • Abstract Number: PB0079

    Inhibitory potential of anticoagulant and antiplatelet agents on COVID-19-induced NETs release

    J. Oliveira1, L. Silva1, G. Damiani1, A. Santos1, B. Jacintho1, C. Vaz1, G. Mesquita2, J. Annichino-Bizzacchi3, B. Mazetto1, E. de Paula4, F. de Andrade Orsi5

  • Abstract Number: OC 01.5

    Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model

    P. Batty1, A. Mo2, M. Ashrafali3, B. Yates3, A. Gonzalez3, B. Handyside3, L. Harpell2, D. Hurlbut2, A. Menard4, A. Pender2, L. Razon3, C. Sihn3, A. Winterborn2, S. Fong3, D. Lillicrap5

  • Abstract Number: OC 56.5

    Insight into genetic predisposition to high plasma levels of Factor VIII (FVIII) and von Willebrand Factor (vWF) in a family with venous thrombosis.

    S. Spena1, A. Cairo1, F. Gianniello1, E. Pappalardo2, M. Mortarino1, I. Garagiola3, I. Martinelli1, F. Peyvandi4

  • Abstract Number: PB0413

    Insights on Antiphospholipid antibody syndrome metabolomics by NMR

    L. Martins1, M. Honorato2, S. Montalvão3, E. Braga1, L. Silva2, E. de Paula4, F. Orsi2, L. Tasic1, J. Annichino-Bizzacchi2

  • Abstract Number: PB0507

    Insulin resistance links to procoagulant clot properties in young adult with type 1 diabetes: a cross-sectional observation study

    N. Kietsiriroje1, S. Pearson2, R. Sagar2, R. Ariëns3, R. Ajjan2

  • Abstract Number: PB1248

    Integrated diagnostic workflow in two siblings with albinism and suspected Hermansky-Pudlak syndrome

    V. Palma-Barqueros1, N. Fernández-Mosteririn2, C. Zaninetti3, N. Pardiñas- Barón4, A. Zamora-Canovas5, A. Sánchez-Fuentes6, N. Revilla7, A. Rodríguez-Alen8, A. Marin-Quilez9, L. Díaz-Ajenjo10, A. Torrecillas6, N. Bohdan6, J. Padilla11, C. Miguel-García9, V. Vicente12, M. Lozano12, A. Greinacher13, J. Bastida14, J. Rivera15

  • Abstract Number: OC 63.2

    Inter-individual FVIII clearance heterogeneity in PWH in the iPATH study – biological determinants and clinical importance.

    E. Elsheikh1, M. Lavin2, N. Larkin3, N. O'Connell3, K. Ryan4, M. Byrne5, E. Singleton4, P. Fallon6, J. Johnsen7, S. Pipe8, P. Turecek9, J. O'Donnell10

  • Abstract Number: PB1360

    Inter-rater reliability of the UK Department of Health VTE risk assessment tool for medical and surgical hospital admissions

    D. Horner1, B. Daniels2, M. Holland3, S. Goodacre4, B. Hunt5, K. de Wit6

  • Abstract Number: PB0739

    Interaction of Antiplatelet and Anticoagulant APAC with Complement Proteins Attenuates Complement Activation via C1q and Factor H

    J. Kotimaa1, M. Rezola1, A. Jouppila2, S. Meri1, R. Lassila3

  • Abstract Number: PB0534

    Interference of PLX038 (pegylated topoisomerase inhibitor SN-38) with coagulation assays

    P. Alcedo Andrade1, P. Desai2, S. Nichols2, K. Nghiem3, N. Patel3, A. Dulau-Florea3, C. Pleyer4, A. Thomas2, C. Bolan4, R. Pruthi5, S. Kalsi6

  • Abstract Number: PB0339

    Interference with dendritic cells by siRNA-CD83 can reverse the polarization of Th1/Th2 and Treg/Th17 in ITP patients

    X. Wang

  • Abstract Number: PB0143

    Interferences in the dosage of D-dimer and variation between methodologies.

    S. Lopes1, R. Penteado2, J. Guerra2, T. Costa2, E. Welter2, V. de Aranda2, A. Villarinho2, B. Fogo2, A. dos Santos2, E. da Silveira2, D. Yamada2, C. Ito2, N. Constantino2, C. Mendes2

  • Abstract Number: PB1153

    Interim Analysis from B-MORE, a 24-month Prospective, Multicentre, Non-interventional Study on Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

    H. Glosli1, S. Ranta2, D. Allsup3, I. Ricca4, M. Saleh5, Å. Carlsheimer6, A. Falk6, E. Santagostino7

  • Abstract Number: VPB0616

    Interleukins that are mostly affected in severe coronavirus disease 2019 (COVID-19)

    M. Meiring1, V. Nkuna1, L. Botes2, F. Smit1

  • Abstract Number: LB 02.1

    Intermediate versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow Study)

    I. Bistervels1, A. Buchmuller2, H. Wiegers3, F. Ní Áinle4, B. Tardy5, J. Donnelly6, P. Verhamme7, A. Jacobsen8, A. Hansen9, M. Rodger10, M. DeSancho11, R. Shmakov12, N. van Es3, M. Prins13, C. Chauleur14, S. Middeldorp15

  • Abstract Number: PB1065

    Interpretation of Coagulation Mixing Study Results in the Era of Direct Oral Anticoagulants

    J. Chen1, M. Losos2

  • Abstract Number: PB1300

    Intestinal Epithelial Protease-Activated Receptor-1 affects Gastrointestinal Motility and the Enteric Nervous System

    G. Pontarollo, O. Dremova, V. Nguyen, K. Endres, C. Reinhardt

  • Abstract Number: PB1137

    Intracranial Haemorrhage in Children with Haemophilia in Turkey

    M. Sezgin Evim1, C. Albayrak2, E. Zengin3, E. Yılmaz4, N. Özdemir5, M. Ertekin6, G. Özdemir7, A. Bahadır8, B. Yılmaz7, S. Akbayram9, F. Küpesiz10, H. Tokgöz11, B. Tatlı Güneş6, Y. Aral12, C. Acıpayam13, F. Belen Apak14, A. UNUVAR15, S. KARAMAN16, H. Ören17

  • Abstract Number: PB0980

    Intravenous Ferric Gluconate Use in Anemic Heart Failure Patients at a Large Academic Medical Center

    S. Coriolan, C. Merchan, A. Katz, T. Ahuja

  • Abstract Number: OC 57.2

    Inversed platelet/fibrin ratio in shear-dependent thrombus formation between patients with COVID-19 and sepsis identifies subtherapeutic GPIIb/IIIa blockade as a potential therapeutic target

    L. Weiss1, M. Drayss2, M. Zeitlhöfler3, K. Mott1, S. Frantz4, B. Nieswandt5, D. Weismann4, H. Schulze6

  • Abstract Number: PB0090

    Investigating Levels of Inflammatory Biomarkers Between SARS-CoV-2 Vaccinated and Unvaccinated Subjects

    N. Jabeen1, A. Amanullah2, M. Hussain2, B. Kantarcioglu3, F. Siddiqui3, J. Fareed3

  • Abstract Number: OC 75.4

    Investigating the health and function of murine platelets generated using a new ex-vivo lung system

    N. Tarassova, X. Zhao, A. Poole

  • Abstract Number: PB0540

    Investigation of GGCX interaction with VKD proteins

    F. Forin1, S. Ghosh1, J. Müller2, J. Oldenburg3, A. Biswas2, K. Czogalla1

  • Abstract Number: PB1280

    Investigation of Podoplanin Signalling Complexes in Primary Lymphatic Endothelial Cells

    T. AL THUNAYAN1, M. Tomlinson2

  • Abstract Number: VPB0228

    Investigation of properties of macropore silica sorbents and active dyes as ligands suitable for purification of factor VIII coagulation

    N. Shurko, T. Danysh, I. Yurchyshak, S. Miliashkevych, V. Novak

  • Abstract Number: PB0533

    Investigation of the epidemiology of inherited deficiency of coagulation factors in patients attending the Royal Hospital, Muscat, Oman

    R. Al Ghaithi, S. Al Hashami, N. Al Amri, S. AL Shiyadi, S. Al Lamki, M. Al Yahyai, M. Al Riyami, M. Al Musalhi, I. Al Salmi

  • Abstract Number: PB1024

    Investigation of thrombin generation assay to assess vaso-occlusive crisis in sickle cell disease

    G. Feugray1, F. Kasonga2, M. Grall3, Y. Benhamou4, V. Le Cam Duchez5, A. Lahary6, P. Billoir7

  • Abstract Number: PB0597

    Investigation of thrombin generation in COVID-19 patients by a care setting design

    G. Tiscia1, A. De Laurenzo1, F. Cappucci1, L. Fischetti1, G. Favuzzi1, D. Colaizzo1, E. Chinni2, E. Grandone3

  • Abstract Number: PB0529

    Investigations of the impact of different bleeding disorders using a humanized in vivo mouse model

    L. Pelzl1, A. Singh2, I. Marini3, K. Althaus1, T. Backchoul4

  • Abstract Number: OC 73.5

    Investigations to assess Impact of Syk-inhibition on antibody-mediated desialylation: novel implications on therapy for immune thrombocytopenia

    A. Singh1, F. Toma2, K. Althaus3, T. Backchoul4

  • Abstract Number: PB0584

    Involvement of The Contact Pathway in COVID-19 Coagulopathy

    M. Capecchi1, C. Novembrino2, M. Abbattista3, M. Boscolo3, S. Griffini3, E. Grovetti3, A. Artoni4, L. Valenti5, D. Prati6, G. Grasselli7, F. Blasi8, M. Cugno3, F. Peyvandi9

  • Abstract Number: VPB0394

    iPSC-Derived Megakaryocytes as a Model to Study Human Platelet Integrin IIb3 Function

    K. Fong1, O. Kim2, A. Gagne3, C. Jobaliya3, J. Maguire3, M. Poncz4, D. French3, R. Litvinov5, J. Weisel6, W. Degrado7, L. Brass1

  • Abstract Number: PB1391

    Iron deficiency in pregnancy is highly prevalent despite suboptimal screening: A population-based cohort study

    A. Alam, V. Jain, P. Kaul, S. Lapner, C. Wu, H. Sun

  • Abstract Number: PO0019

    Iron deficiency reduces mitochondrial respiration in skeletal muscle

    K. Cabolis1, T. Richards2, K. Smith1, M. Sajic1

  • Abstract Number: VPB0576

    Is plasma-derived coagulation factor Xa safe for reversal of direct factor Xa inhibitor?

    S. Surov, W. Jankowski, Z. Sauna, M. Ovanesov

  • Abstract Number: PB1243

    ITGB3/ITGA2B-related platelet disorders: phenotypic and genetic aspects of a series of 20 families evaluated in a single centre

    C. Monteiro1, A. Gonçalves2, M. Pereira3, M. Gonçalves4, C. Lau4, E. Cruz5, R. Santos6, S. Morais7

  • Abstract Number: PB1198

    ITP before and after COVID-19 vaccinations: a national cohort study

    P. Choi1, D. Hsu2, J. Curnow3, C. TAN4, A. Enjeti5, H. Tran6, V. CHEN7, A. Yong8, F. Roncolato9, J. Simpson10, D. Pepperell11, R. Bird12

Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley